MeiraGTx (MGTX) Projected to Post Quarterly Earnings on Thursday

MeiraGTx (NASDAQ:MGTX) is anticipated to release its earnings data on Thursday, March 13th. Analysts expect MeiraGTx to post earnings of ($0.48) per share for the quarter.

MeiraGTx Price Performance

Shares of MGTX stock opened at $6.58 on Thursday. The stock has a market capitalization of $514.25 million, a PE ratio of -5.44, a PEG ratio of 0.37 and a beta of 1.23. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.34 and a current ratio of 2.34. The stock’s fifty day moving average is $6.45 and its 200-day moving average is $5.69. MeiraGTx has a 52 week low of $3.85 and a 52 week high of $7.80.

Insider Transactions at MeiraGTx

In related news, CEO Alexandria Forbes sold 35,839 shares of MeiraGTx stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $6.47, for a total value of $231,878.33. Following the completion of the transaction, the chief executive officer now owns 1,395,102 shares in the company, valued at approximately $9,026,309.94. This trade represents a 2.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Richard Giroux sold 24,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $6.29, for a total value of $150,960.00. Following the transaction, the chief financial officer now owns 849,947 shares of the company’s stock, valued at $5,346,166.63. This trade represents a 2.75 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 8.40% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Chardan Capital reissued a “buy” rating and set a $36.00 price target on shares of MeiraGTx in a report on Monday, February 24th. Royal Bank of Canada increased their price objective on MeiraGTx from $9.00 to $11.00 and gave the stock an “outperform” rating in a research note on Thursday, November 14th.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.